Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 754091 alone or with BI 836880 in chemotherapy-resistant metastatic anal squamous cell carcinoma
NL-OMON49049Phase 2Withdrawn
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in anal squamous cell carcinoma (SCCA) and anal cancer comparing BI 754091 monotherapy with BI 754091 + BI 836880 (2 arms). Primary endpoint: Objective response. Planned start Jul 2020; status: withdrawn.
02
Drugs
ezabenlimabBI 836880
03
Conditions
anal squamous cell carcinoma (SCCA)anal cancer
Beyond the preview
Go deeper on NL-OMON49049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49049.